Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

October 28, 2019 updated by: Galderma R&D

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1212

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Czechia
      • Chomutov, Czechia, 430 04
        • Galderma Investigational Site
      • Hradec Kralove, Czechia, 500 05
        • Galderma Investigational Site
      • Kutna Hora, Czechia, 284 01
        • Galderma Investigational Site
      • Olomouc, Czechia, 775 20
        • Galderma Investigational Site
      • Pardubice, Czechia, 532 03
        • Galderma Investigational Site
      • Praha, Czechia, 190 11
        • Galderma Investigational Site
      • Praha 1, Czechia, 11 000
        • Galderma Investigational Site
      • Praha 1, Czechia, 110 00
        • Galderma Investigational Site
  • Hungary
      • Budapest, Hungary, 1035
        • Galderma Investigational Site
      • Budapest, Hungary, 1089
        • Galderma Investigational Site
      • Debrecen, Hungary, 4032
        • Galderma Investigational Site
      • Miskolc, Hungary, 3529
        • Galderma Investigational Site
      • Pecs, Hungary, 7632
        • Galderma Investigational Site
      • Szeged, Hungary, 6720
        • Galderma Investigational Site
      • Szolnok, Hungary, 5000
        • Galderma Investigational Site
  • Poland
      • Bialystok, Poland, 15-453
        • Galderma Investigational Site
      • Gdansk, Poland, 80-152
        • Galderma Investigational Site
      • Gdansk, Poland, 80-402
        • Galderma Investigational Site
      • Gdansk, Poland, 80-546
        • Galderma Investigational Site
      • Katowice, Poland, 40-036
        • Galderma Investigational Site
      • Katowice, Poland, 40-611
        • Galderma Investigational Site
      • Katowice, Poland, 40-851
        • Galderma Investigational Site
      • Lodz, Poland, 90-242
        • Galderma Investigational Site
      • Sochaczew, Poland, 95-500
        • Galderma Investigational Site
      • Warszawa, Poland, 01-817
        • Galderma Investigational Site
      • Warszawa, Poland, 02-657
        • Galderma Investigational Site
      • Warszawa, Poland, 02-758
        • Galderma Investigational Site
      • Wroclaw, Poland, 51-318
        • Galderma Investigational Site
      • Wroclaw, Poland, 53-658
        • Galderma Investigational Site
  • Romania
      • Brasov, Romania, 500283
        • Galderma Investigational Site
      • Craiova, Romania, 200642
        • Galderma Investigational Site
      • Iasi, Romania, 700381
        • Galderma Investigational Site
      • Târgu-Mureş, Romania, 540530
        • Galderma Investigational Site
  • Russian Federation
      • Krasnodar, Russian Federation, 3500 20
        • Galderma Investigational Site
      • Lipetsk, Russian Federation, 398035
        • Galderma Investigational Site
      • Moscow, Russian Federation, 107076
        • Galderma Investigational Site
      • Moscow, Russian Federation, 119071
        • Galderma Investigational Site
      • Moscow, Russian Federation, 121614
        • Galderma Investigational Site
      • Sr Petersburg, Russian Federation, 194021
        • Galderma Investigational Site
      • St Petersburg, Russian Federation, 194100
        • Galderma Investigational Site
  • Spain
      • Barcelona, Spain, 08206
        • Galderma Investigational Site
      • Esplugues de Llobregat, Spain, 8950
        • Galderma Investigational Site
      • Madrid, Spain, 28009
        • Galderma Investigational Site
      • Valencia, Spain, 46014
        • Galderma Investigational Site
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49044
        • Galderma Investigational Site
      • Dnipropetrovsk, Ukraine, 49074
        • Galderma Investigational Site
      • Ivano-Frankivsk, Ukraine, 76000
        • Galderma Investigational Site
      • Kharkiv, Ukraine, 61057
        • Galderma Investigational Site
      • Kyiv, Ukraine, 01601
        • Galderma Investigational Site
      • Kyiv, Ukraine, 04209
        • Galderma Investigational Site
      • Lviv, Ukraine, 79049
        • Galderma Investigational Site
      • Uzhgorod, Ukraine, 88000
        • Galderma Investigational Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35205
        • Galderma Investigational Site
    • Arizona
      • Phoenix, Arizona, United States, 85032
        • Galderma Investigational Site
      • Tucson, Arizona, United States, 85712
        • Galderma Investigational Site
    • Arkansas
      • Fort Smith, Arkansas, United States, 72916
        • Galderma Investigational Site
    • California
      • Los Angeles, California, United States, 90036
        • Galderma Investigational Site
      • Murrieta, California, United States, 92562
        • Galderma Investigational Site
      • Santa Ana, California, United States, 92705
        • Galderma Investigational Site
    • Florida
      • Aventura, Florida, United States, 33180
        • Galderma Investigational Site
      • Miami, Florida, United States, 33144
        • Galderma Investigational Site
      • Miami Lakes, Florida, United States, 33016
        • Galderma Investigational Site
      • West Palm Beach, Florida, United States, 33406
        • Galderma Investigational Site
    • Kentucky
      • Corbin, Kentucky, United States, 40701
        • Galderma Investigational Site
    • Massachusetts
      • Beverly, Massachusetts, United States, 01915
        • Galderma Investigational Site
    • Michigan
      • Ann Arbor, Michigan, United States, 48103
        • Galderma Investigational Site
      • Detroit, Michigan, United States, 48202
        • Galderma Investigational Site
    • New York
      • Brooklyn, New York, United States, 11203
        • Galderma Investigational Site
      • Stony Brook, New York, United States, 11790
        • Galderma Investigational Site
    • North Carolina
      • Wilmington, North Carolina, United States, 28401
        • Galderma Investigational Site
    • Pennsylvania
      • Fort Washington, Pennsylvania, United States, 19034
        • Galderma Investigational Site
      • Philadelphia, Pennsylvania, United States, 19103
        • Galderma Investigational Site
    • South Carolina
      • Greer, South Carolina, United States, 29650
        • Galderma Investigational Site
    • Tennessee
      • Goodlettsville, Tennessee, United States, 37072
        • Galderma Investigational Site
    • Texas
      • Austin, Texas, United States, 78759-8858
        • Galderma Invetsigational site
      • Dallas, Texas, United States, 75230-5806
        • Galderma Investigational Site
      • Houston, Texas, United States, 77004
        • Galderma Investigational Site
      • Pflugerville, Texas, United States, 78660
        • Galderma Investigational Site
      • San Antonio, Texas, United States, 78249
        • Galderma Investigational Site
      • Webster, Texas, United States, 77598
        • Galderma Investigational Site
    • Washington
      • Walla Walla, Washington, United States, 99362
        • Galderma Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

5 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The subject is a male or female, 9 years of age or older, at Screening visit.
  • The Subject has moderate acne at Screening and Baseline.
  • The subject is a female of non childbearing potential
  • The subject is a female of childbearing potential with a negative pregnancy test and who is strictly abstinent or who agrees to use an effective and approved contraceptive method for the duration of the study and at least 1 month after the last study drug application.

Exclusion Criteria:

  • The subject has severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g.,chloracne, drug-induced acne, etc.).
  • The subject has any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part to the trial.
  • The subject has been exposed to excessive ultraviolet (UV) radiation within one month prior to the Baseline visit or the subject is planning intense UV exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.)
  • The subject is unwilling to refrain from use of prohibited medication during the clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: CD5789 (Trifarotene) 50µg/g Cream
CD5789 (trifarotene) 50µg/g Cream
Drug: CD5789 (trifarotene) 50µg/g Cream
CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
Placebo Comparator: Placebo Cream
Drug: Placebo Cream
Placebo cream applied once daily during 12 weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
Time Frame: From Baseline to Week 12
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
From Baseline to Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Galderma R&D

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 7, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 12, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 18, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 21, 2015

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 28, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RD.06.SPR.18252

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings